HRMYHealthcare · BiotechnologyThe 11 Wall Street analysts covering Harmony Biosciences Holdings, Inc. hold a median 12-month price target of $50 — +19.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 18 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Harmony Biosciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HRMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Aug 2026 | Wolfe Research | Initiates | Outperform | $60 |
| 5 Aug 2026 | Truist Securities | Maintains | Hold | $29 → $34 |
| 5 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 4 Aug 2026 | Needham | Maintains | Buy | $45 → $50 |
| 4 Aug 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Mizuho | Maintains | Outperform | — |
| 31 July 2026 | Mizuho | Maintains | Outperform | $50 → $51 |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $55 |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2026 | Deutsche Bank | Maintains | Hold | — |
| 8 May 2026 | Truist Securities | Maintains | Hold | — |
| 25 Feb 2026 | B of A Securities | Maintains | Underperform | — |
| 25 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2026 | Needham | Maintains | Buy | — |
| 25 Feb 2026 | UBS | Maintains | Neutral | — |
| 11 Feb 2026 | UBS | Downgrade | Neutral | — |
| 8 Jan 2026 | Truist Securities | Maintains | Buy | — |
| 1 Dec 2025 | Mizuho | Maintains | Outperform | — |
| 24 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Nov 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HRMY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Harmony Biosciences Holdings, Inc. returned +28.8% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 46% of US stocks
Cheaper than 38% of US stocks
Cheaper than 46% of US stocks
Higher than 78% of US stocks
Higher than 82% of US stocks
Higher than 88% of US stocks
Higher than 89% of US stocks
Higher than 81% of US stocks
Higher than 81% of US stocks
Higher than 94% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Harmony Biosciences Holdings, Inc. has a market value of $2.4B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $959.9M. The latest quarter grew 30.3% year on year.
Net income over the same four quarters: $181.3M, a 18.9% net margin.
Diluted earnings per share, trailing twelve months: $3.08.
Free cash flow in the twelve months to 30 June 2026: $354.9M.
Trailing P/E: 13.6×; forward P/E: 6.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Harmony Biosciences Holdings, Inc. employs 293 people — $3.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Harmony Biosciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Harmony Biosciences reported earnings 30 days ago, and its stock has risen 12.1% since that report. The news notes this price movement and asks what may be next for the company.
Why it matters — HRMY watchers would care because the post-earnings stock gain reflects how the market has responded to the company's latest financial report.
Harmony Biosciences announced it will present encore data from its investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress, to be held September 5-9 in Athens, Greece.
Why it matters — The presentation provides Harmony Biosciences' EPX-100 epilepsy program with additional visibility at an international medical conference.
Harmony Biosciences Holdings, Inc. announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 10:20 a.m. ET.
Why it matters — This event gives HRMY watchers an opportunity to hear directly from the company's management team at a major healthcare investment conference.
At Piper Sandler's virtual CNS Symposium, Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy, and pitolisant lifecycle-management programs.
Why it matters — A Harmony Biosciences watcher would care because the company's record WAKIX quarterly results and progress across its orexin, epilepsy, and pipeline programs indicate ongoing momentum in its core narcolepsy franchise and future development plans.
Zacks Investment Research highlighted HRMY among four healthcare stocks to watch as defensive demand strengthens in 2026, citing improving earnings outlooks and steady sector momentum for the group.
Why it matters — HRMY watchers would care because the item places the company among healthcare names with improving earnings outlooks amid strengthening defensive demand.
The 11 Wall Street analysts covering Harmony Biosciences Holdings, Inc. have a median 12-month price target of $50, with estimates ranging from $30 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Harmony Biosciences Holdings, Inc., 7 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Harmony Biosciences Holdings, Inc. 85 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 18 Sept 2026, Harmony Biosciences Holdings, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +19.0% from the last close, and Ticker Nerd's factor model ranks Harmony Biosciences Holdings, Inc. 85 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Harmony Biosciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HRMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $70 over the next 12 months.
Harmony Biosciences Holdings, Inc. returned +28.8% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs.
The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?". Harmony Biosciences reported earnings 30 days ago, and its stock has risen 12.1% since that report. The news notes this price movement and asks what may be next for the company.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs. The company’s portfolio centers on treatments for sleep-wake disorders and related neurological conditions, with a strong emphasis on patients whose options remain limited. Its marketed therapy, WAKIX, is designed for the treatment of excessive daytime sleepiness in adults with narcolepsy, reflecting the company’s focus on specialized neuroscience care. Harmony Biosciences also advances research programs in adjacent rare neurological and endocrine disorders, combining commercial operations with clinical development capabilities. Headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences plays a focused role in the biopharmaceutical market by addressing niche patient populations through targeted, science-driven therapies.
CEO Dr. Jeffrey M. Dayno M.D. · 293 employees · United States · https://www.harmonybiosciences.com
